{"schema_version":"1.0","type":"article","title":"歷史性一刻，世紀大藥來了","url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.md","lang":"zh-Hant","date":"2026-04-20","publish_at":"2026-04-20T10:30:00+08:00","updated_at":"2026-04-20","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資"],"summary":"4 月 13 日，Revolution Medicines 公布 daraxonrasib（RMC-6236） 在三期臨床 RASolute 302 的頂線結果。","key_points":[],"facts":[],"sections":["歷史性一夜：daraxonrasib 如何把 RAS 靶向治療推進新紀元","🔹 這組結果之所以震撼，不只是因為數字漂亮，而是因為它發生在胰臟癌","🧬 daraxonrasib 的不同，正在於它不是再做一顆更好的 G12C 抑制劑，而是試圖直接改寫整個 RAS 靶向的作用邏輯","📊 其實，在這次三期之前，市場就已經從早期資料看出它不只是概念","💰 資本市場的反應，也幾乎是瞬間完成重估","🚀 這種加速，其實已經開始發生","✨ 所以，這場 4 月 13 日的「歷史性一夜」，真正重要的其實有兩層"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"\"Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer","source":"Revolution Medicines\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Emerging landscape of KRAS inhibitors in cancer treatment","source":"","date":"","url":""},{"title":"RAS mutations drive ∼20% of human cancers. This review summarizes clinical outcomes and resistance mechanisms of KRASG12C inhibitors and highlights emerging classes of next-generation (K)RAS inhibitors, focusing on their mechanisms of action, selectivity,","source":"","date":"","url":""},{"title":"www.cell.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"https://www.sciencedirect.com/org/science/article/pii/S1520480425002959","source":"","date":"","url":"https://www.sciencedirect.com/org/science/article/pii/S1520480425002959"},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"www.asco.org","source":"","date":"","url":""},{"title":"https://www.asco.org/abstracts-presentations/241485","source":"","date":"","url":"https://www.asco.org/abstracts-presentations/241485"},{"title":"www.asco.org","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"\"Revolution Medicines' experimental cancer pill boosts survival in late-stage study","source":"Reuters\"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：歷史性一刻，世紀大藥來了（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-01.webp"},{"alt":"Dcard 原圖：歷史性一刻，世紀大藥來了（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-02.webp"},{"alt":"Dcard 原圖：歷史性一刻，世紀大藥來了（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-03.webp"},{"alt":"Dcard 原圖：歷史性一刻，世紀大藥來了（圖 4）","url":"https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-20）。歷史性一刻，世紀大藥來了。https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-20-dcard-261332702-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}